发明名称 Treatment of type 1 diabetes
摘要 The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.;
申请公布号 US9271984(B2) 申请公布日期 2016.03.01
申请号 US201113703147 申请日期 2011.06.09
申请人 POXEL 发明人 Fouqueray Pascale;Cravo Daniel;Hallakou-Bozec Sophie;Bolze Sébastien
分类号 A01N43/66;A61K31/53;A61K9/20 主分类号 A01N43/66
代理机构 Nixon & Vanderhye P.C. 代理人 Nixon & Vanderhye P.C.
主权项 1. A method for protecting beta cells from cellular death to thereby delay the onset of type 1 diabetes, comprising administering to a patient in need thereof who is at risk of developing type 1 diabetes due to the presence of antibodies characteristic of the disease but who does not have all the symptoms of type 1 diabetes, an effective amount of a triazine derivative selected in the group consisting of 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine, a racemic form, tautomer, enantiomer, diastereoisomer and epimer thereof, and a pharmaceutically acceptable salt thereof thereby delaying the onset of type 1 diabetes by protecting beta cells from cellular death, said patient not having been administered insulin in a range of less than 24 hours before or after administration of the triazine derivative.
地址 Lyon FR